AstraZeneca: halts studies for brazikumab
(CercleFinance.com) - AstraZeneca has today announced the discontinuation of the development program for brazikumab in chronic inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC).
The development programme for brazikumab in IBD included a phase IIb/III trial in CD and a phase II trial in UC, as well as their respective open-label extension trials.
The decision to halt development of brazikumab in IBD follows a recent review of the brazikumab development timetable (notably impacted by delays that have not been compensated) and the context of an ever-changing competitive landscape.
The company states that no safety issues have been identified for patients in these trials and reports that under a 2020 agreement, AbbVie had contributed to the ongoing funding of the development program but that this funding will now cease.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The development programme for brazikumab in IBD included a phase IIb/III trial in CD and a phase II trial in UC, as well as their respective open-label extension trials.
The decision to halt development of brazikumab in IBD follows a recent review of the brazikumab development timetable (notably impacted by delays that have not been compensated) and the context of an ever-changing competitive landscape.
The company states that no safety issues have been identified for patients in these trials and reports that under a 2020 agreement, AbbVie had contributed to the ongoing funding of the development program but that this funding will now cease.
Copyright (c) 2023 CercleFinance.com. All rights reserved.